Pharmaceuticals, Biotechnology & Life Sciences

Danaher insider sale: Couchara Georgeann sells 101 shares at $209, amid broader executive activity and upcoming acquisitions—what this means for investors.

Insider selling spurs analysis of Cullinan Therapeutics’ stock trend and potential liquidity strategy—what it means for investors.

Nehall’s recent buy‑sell at Supernus signals cautious optimism—balanced insider confidence that could hint at a short‑term rally.

Insider buying signals at Silexion Therapeutics: Noy Shlomo’s steady share purchases and CEO‑level stakes hint at confidence in the RNAi pipeline, suggesting potential undervaluation and long‑term upside for investors.

Ardelyx CEO Michael Raab’s recent insider trades—buying 20,833 shares at $0.99 and selling 41,666 at $6.26—show disciplined liquidity management and long‑term confidence in the company’s growth strategy.

Insider buying spurs confidence in Cocrystal Pharma (CRP) as executives accumulate shares ahead of key norovirus data, suggesting a potential upside for investors.

Insightful look at Amylyx’s insider sales: Mazzariello’s tax‑withholding trades, their impact on stock, and what they reveal about the company’s future.

Planet 13 insider Wren Chris’s February 20 buy backs 30,000 shares at $0.17, signaling cautious confidence as the company pivots to core Nevada operations and refocuses after shedding California assets.

Caribou Biosciences insiders, led by CTO Kelly Timothy, buy and sell shares amid volatile pricing—showing confidence, potential upside, and a balanced investment outlook.

Investor insight: Aurentz Vincent’s sale of 255k IKT shares may signal strategic rebalancing, not a sell‑off warning, with bullish sentiment and a Buy rating.